Literature DB >> 31088041

A Neurofibromatosis Noonan Syndrome Patient Presenting with Abnormal External Genitalia

Esra Işık1, Hüseyin Onay2, Tahir Atik1, Aslı Ece Solmaz2, Samim Özen3, Özgür Çoğulu1,2, Şükran Darcan3, Ferda Özkınay1,2.   

Abstract

Neurofibromatosis Noonan syndrome (NFNS) is a rare RASopathy syndrome, resulting from NF1 gene mutations. NFNS is characterized by phenotypic features of both neurofibromatosis type 1 (NF1) and Noonan syndrome. Plexiform neurofibromas (PNFs) are an unusual finding in NFNS. A seven year-old girl with typical clinical features of NF1 was referred to our clinic due to short stature and abnormal genital appearance. Due to dysmorphic features, a clinical diagnosis of NFNS was considered in the patient and, following molecular analysis, revealed a novel heterozygous c.3052_3056delTTAGT (p.L1018X) variant in the NF1 gene. Although evaluation for genital virilization, including karyotype and hormonal studies were normal, imaging studies revealed a diffuse genital PNF. Although PNFs are seen rarely in NFNS, this should be considered in the differential diagnosis of genital virilization in these patients to prevent unnecessary testing.

Entities:  

Keywords:  NF1 gene; abnormal external genitalia; Neurofibromatosis Noonan syndrome

Year:  2019        PMID: 31088041      PMCID: PMC7127889          DOI: 10.4274/jcrpe.galenos.2019.2019.0023

Source DB:  PubMed          Journal:  J Clin Res Pediatr Endocrinol


What is already known on this topic?

The Neurofibromatosis Noonan syndrome (NFNS) is a rare RASopathy syndrome characterized by phenotypic features of both neurofibromatosis type 1 (NF1) and NS. It occurs as a result of NF1 gene mutations. Plexiform neurofibromas (PNFs) are seen rarely in NFNS patients.

What this study adds?

A novel mutation in the NF1 gene in a patient who presented with phenotypic features of both NF1 and NS is reported. A PNF was present in this case and was responsible for an unusual genital phenotype. Thus PNF may be a rare cause of genital virilization in NFNS patients.

Introduction

Neurofibromatosis Noonan syndrome (NFNS) (OMIM 601321) is a rare RASopathy syndrome, first defined in four unrelated patients in 1985 by Allanson et al (1). These patients who were originally diagnosed as neurofibromatosis type 1 (NF1), also presented with clinical features of NS. NFNS patients show phenotypic features of both NF1 and NS. In subsequent years several cases showing clinical findings of both syndromes have been reported, thus introducing a new phenotypic syndrome; NFNS. NFNS has been shown to be due to heterozygous mutations in the NF1 gene (2). Neurofibromas are benign peripheral nerve sheath tumors and are classified as either dermal or plexiform neurofibromas (PNFs) (3). PNFs are usually congenital and originate from a bundle of fascicles or a large nerve plexus. PNFs can be seen in 25-50% of NF1 patients (4). However, they are more rarely seen in NFNS patients. It has been reported that in pediatric NF1 patients PNFs are most commonly localized in the head and neck region (4,5). Genital localization of PNFs has been reported rarely. In this study, we report a young girl with NFNS and a genital PNF manifesting as abnormal external genitalia giving the impression of a disorder of sex development (DSD).

Case Report

A seven year-old girl with typical clinical features of NF1 was referred to our clinic due to short stature and abnormal genital appearance. She was born at the 37th week of gestation with a birth weight and height of 2800 gr (10-25th centile) and 47 cm (10-25th centile), respectively. During the newborn period multiple café-au-lait spots and spina bifida were observed. Her neuromotor development was normal. At the age of three years an operation was performed for filum terminale lipoma. A family history revealed her father had similar clinical features. On physical examination, weight, height and head circumference were measured as 18 kg (3-10th percentile), 106 cm (<3rd percentile), 54 cm (>97th percentile), respectively. She had macrocephaly, broad forehead, sparse eyebrows, depressed nasal bridge, hypertelorism, low set ears, deeply grooved philtrum, short and webbed neck, pectus excavatum, kyphoscoliosis, sacral hypertrichosis, multiple cafe-au-lait spots and axillary and inguinal freckling (Figure 1). On genital examination, abnormal external genitalia were observed. A genital structure resembling a phallus was measured as 3.5 cm. Genital appearance was evaluated as being Prader Stage 2. No Lisch nodule was detected via slit-lamp examination. Echocardiography was normal. Cranial magnetic resonance imaging (MRI) revealed a hamartoma.
Figure 1

Phenotypic findings of the patient. A, B) Dysmorphic features: macrocephaly, broad forehead, sparse eyebrows, depressed nasal bridge, hypertelorism, low set ears, deeply grooved philtrum, short and webbed neck, pectus excavatum and multiple cafe-au-lait spots. C) Cliteromegaly

Due to clinical features including macrocephaly, short stature, facial dysmorphism, webbed and short neck and pectus excavatum in addition to the typical findings of NF1, a clinical diagnosis of NFNS was considered in the patient. All coding exons and the flanking intronic regions of the NF1 (NM_000267.3) and the PTPN11 (NM_002834) genes were amplified by polymerase chain reaction and sequenced using Illumina MiSeq platform (Illumina Ltd., San Diego, USA). Molecular analysis revealed a novel heterozygous c.3052_3056delTTAGT (p.L1018X) variant in the NF1 gene (Figure 2). In accordance with the American College of Medical Genetics recommendations (null variant, hot-spot region, variant not found in public databases) this variant has been predicted as pathogenic (6).
Figure 2

Next generation sequencing analysis in the patient demonstrating a heterozygous NF1 mutation; c.3052_3056delTTAGT (p.L1018X)

Laboratory tests for genital virilization, including karyotype (46,XX), thyroid function, follicle stimulating hormone, luteinizing hormone, estradiol, testosterone, 17-hydroxyprogesterone, 11-deoxycorticosterone, dehydroepiandrosterone sulphate, adrenocorticotropic hormone and cortisol concentrations and bone age were all normal (Table 1). MRI of the pelvis and external genitalia showed multiple PNFs filling the pelvic area with invasion of the sacral neural foraminae and subcutaneous region. Additionally, multiple neurofibromas were detected in the labium majus and the external genital area (Figure 3).
Table 1

Hormone concentrations of the patient at presentation

Figure 3

Magnetic resonance imaging of abdomen and external genitalia: multiple plexiform neurofibromas filling the pelvic area with invasion of the sacral neural foraminae and subcutaneous region, multiple neurofibromas in the labium majus and the external genital area

Discussion

NS and NF1 are both included within the group of conditions known as the RASopathy syndromes. However, distinct clinical and genetic differences exist. The patient presented here had a number of features typical of both syndromes. NS is genetically heterogeneous. To date at least 14 genes, the most common being PTPN11, have been implicated in the etiology of NS (7). NF1 patients have characteristics different to NS while carrying NF1 gene deletions or point mutations (2,8). To date, a number of cases, showing characteristic cardinal findings of both syndromes together with NF1 gene mutations have been reported in the literature. Among NFNS patients, several patients were found to have mutations in both PTPN11 and NF1. The majority of NFNS patients, however, have been reported to have only NF1 mutations, without any detectable PTPN11 mutation. Thus NFNS syndrome has been attributed to NF1 mutations by most authors. In our patient, following sequencing of both NF1 and PTPN11 genes, the only pathogenic variant found was in NF1 (9). In NF1 patients mutations may appear anywhere throughout the entire gene. However, in the majority of NFNS patients, mutations have been localized within the GTPase-activating-protein (GAP) related domain (2). Consistent with this, the novel frameshift mutation observed in our patient was localized in the GAP related domain. Disorders of sex development are classified into three groups (sex chromosome DSD, 46,XY DSD and 46,XX DSD) based on karyotype (10). In 46,XX DSD the genotype is 46,XX and the gonads present as ovaries; however, the external genitalia shows virilization (11). Virilization of external genitalia is rarely caused anything other than hormonal factors. Due to the abnormal appearance of the external genital organs in this case, a differential diagnosis for DSD was necessary. To exclude 46,XX DSD, hormonal tests were performed and they were all found to be normal. Subsequent imaging studies revealed a diffuse PNF which resulted in clitoral and labial enlargement in the patient. PNFs in external genital organs have rarely been described in NF1 patients (12,13) and to date there have been no reports of NFNS patients with PNFs invading the external genitalia. In the current literature, the hormonal analyses of all NF1 patients with genital abnormality have been found to be normal (12,13,14,15). Neurofibromas are benign tumors, however their invasive nature and size may require surgical intervention. In almost 50% of PNFs involving the genital area, surgical intervention has been required (4). Unfortunately surgical correction was not an option for our patient due to the extensive involvement of the PNF in the pelvic area and the patient was started on sirolimus treatment, as this was seen as the most appropriate form of treatment. Firstly, if a patient presents with the clinical features of both NS and NF1, NFNS should be considered. Secondly, in NFNS, as in NF1, genital PNF is an unusual clinical finding and could present as abnormal external genitalia giving the impression of a DSD. Imaging studies, prior to extensive hormonal work-up, should be performed to rule this out.
  15 in total

1.  Noonan phenotype associated with neurofibromatosis.

Authors:  J E Allanson; J G Hall; M I Van Allen
Journal:  Am J Med Genet       Date:  1985-07

2.  Prognostic signs in the surgical management of plexiform neurofibroma: the Children's Hospital of Philadelphia experience, 1974-1994.

Authors:  M N Needle; A Cnaan; J Dattilo; J Chatten; P C Phillips; S Shochat; L N Sutton; S N Vaughan; E H Zackai; H Zhao; P T Molloy
Journal:  J Pediatr       Date:  1997-11       Impact factor: 4.406

3.  NF1 mutations in neurofibromatosis 1 patients with plexiform neurofibromas.

Authors:  Lan Kluwe; Reinhard E Friedrich; Bruce Korf; Raimund Fahsold; Victor-F Mautner
Journal:  Hum Mutat       Date:  2002-03       Impact factor: 4.878

Review 4.  Localized neurofibromatosis of the female genital system: a case report and review of the literature.

Authors:  Ana M Gómez-Laencina; Francisco Martínez Díaz; Blanca Izquierdo Sanjuanes; Elena M Vicente Sánchez; Rosario Fernandez Salmerón; Francisco Meseguer Peña
Journal:  J Obstet Gynaecol Res       Date:  2012-04-09       Impact factor: 1.730

5.  Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1.

Authors:  Carlos E Prada; Fatima A Rangwala; Lisa J Martin; Anne M Lovell; Howard M Saal; Elizabeth K Schorry; Robert J Hopkin
Journal:  J Pediatr       Date:  2011-10-11       Impact factor: 4.406

Review 6.  Neurofibromatosis type 1.

Authors:  David H Gutmann; Rosalie E Ferner; Robert H Listernick; Bruce R Korf; Pamela L Wolters; Kimberly J Johnson
Journal:  Nat Rev Dis Primers       Date:  2017-02-23       Impact factor: 52.329

Review 7.  Disorders of sex development: a new definition and classification.

Authors:  Ieuan A Hughes
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-02       Impact factor: 4.690

8.  NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome.

Authors:  Alessandro De Luca; Irene Bottillo; Anna Sarkozy; Claudio Carta; Cinzia Neri; Emanuele Bellacchio; Annalisa Schirinzi; Emanuela Conti; Giuseppe Zampino; Agatino Battaglia; Silvia Majore; Maria M Rinaldi; Massimo Carella; Bruno Marino; Antonio Pizzuti; Maria Cristina Digilio; Marco Tartaglia; Bruno Dallapiccola
Journal:  Am J Hum Genet       Date:  2005-10-26       Impact factor: 11.025

9.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

10.  Noonan syndrome - a new survey.

Authors:  Alireza Tafazoli; Peyman Eshraghi; Zahra Kamel Koleti; Mohammadreza Abbaszadegan
Journal:  Arch Med Sci       Date:  2016-12-19       Impact factor: 3.318

View more
  1 in total

Review 1.  LZTR1 molecular genetic overlap with clinical implications for Noonan syndrome and schwannomatosis.

Authors:  Kirsten M Farncombe; Emily Thain; Carolina Barnett-Tapia; Hamid Sadeghian; Raymond H Kim
Journal:  BMC Med Genomics       Date:  2022-07-15       Impact factor: 3.622

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.